DMPK and myotonic dystrophy type 1: The inhibition of CUG-expanded DMPK mRNAs and their pathogenic interaction with RBPs by antisense oligonucleotides is the focus of extensive research studies that have shown their strong potential to reverse DM1-like symptoms in multiple transgenic mouse models.